(Q45154772)

English

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

G Masi

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

G Allegrini

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

S Cupini

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

L Marcucci

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

E Cerri

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

I Brunetti

6

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

E Fontana

7

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

S Ricci

8

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

M Andreuccetti

9

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

A Falcone

10

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1766-1772

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Scheduling of fluorouracil: a forget-me-not in the jungle of doublets

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

First-line treatment strategies to improve survival in patients with advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH470

21 January 2018

Identifiers

10.1093/ANNONC/MDH470

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45154772&oldid=2068147208"